Aarti Pharmalabs Limited (NSE:AARTIPHARM)

Market Cap	80.60B +6.9%
Revenue (ttm)	19.69B +1.2%
Net Income	2.05B -23.1%
EPS	22.56 -23.2%
Shares Out	90.68M
PE Ratio	39.67
Forward PE	49.93
Dividend	3.50 (0.39%)
Ex-Dividend Date	Sep 15, 2026

Volume	464,260
Open	873.20
Previous Close	872.70
Day's Range	870.05 - 898.55
52-Week Range	585.00 - 1,002.40
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About Aarti Pharmalabs

Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, ophthalmologic, antidepressant medications. It also ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Employees: 2,421
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: AARTIPHARM

Financial Performance

In fiscal year 2026, Aarti Pharmalabs's revenue was 18.19 billion, a decrease of -13.98% compared to the previous year's 21.15 billion. Earnings were 1.75 billion, a decrease of -35.86%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 2, 2026

Data Sources Report a data error